Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Amy Raskin, CIO at Chevy Chase Trust, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Super Bowl 2025: ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Vertex provided 2025 revenue guidance of $11.75 billion to $12 billion, reflecting 8% growth at the midpoint. Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

Vertex Pharmaceuticals Inc. (VRTX) on Monday reported fourth-quarter profit of $913 million. The Boston-based company said it had net income of $3.50 per share.